Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company's lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is based in Toronto, Canada.…
Quantum BioPharma (QNTM) Reports $12.22M in Cash and Digital Assets, Advances Lucid-MS Phase 2 Trial
Quantum BioPharma (NASDAQ: QNTM) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 1.290 USD on 20 November 2026, down 85.0% over 52 weeks. Its 52-week range is 1.260 USD to 12.42 USD: the price is 89.6% below the high and 2.4% above the low.
Its market capitalisation is 8.29M USD.
Quantum BioPharma reports return on equity of -378.0% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 2.89M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.